AH
Andreessen Horowitz (a16z) Bio + Health
Andreessen Horowitz (a16z) Bio + Health focuses on investing in therapeutic platforms and cutting-edge technology companies that leverage the convergence of AI, technology, and biology to drive transformative progress in human health. Their strategy involves backing entrepreneurs across all stages, from company creation to growth, to build a modern, efficient, and enduring healthcare system that improves patient care and addresses systemic challenges.
50% of their portfolio is in Healthcare. Their most common stage is series-b (50% of deals). Average disclosed round size is $58.0M (across 8 rounds with reported amounts).
Portfolio
8
Fund Size
$700M
Top Stage
Series B
Last 12 Mo
2
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
8 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Gate Bioscience | Series B | $65M | Nov 2025 |
 Sprinter Health | Series B | $55M | May 2025 |
 Counsel Health | Seed | $11M | Oct 2024 |
 Pomelo Care | Series B | $46M | Jun 2024 |
 Hippocratic AI | Series C | $53M | Mar 2024 |
 Inductive Bio | Seed | $4.3M | Dec 2023 |
 Tome Biosciences | Series B | $213M | Dec 2023 |
 Bold | Series A | $17M | Sep 2023 |
Top Co-Investors
GV (Google Ventures)3 shared
ARCH Venture Partners2 shared
General Catalyst2 shared
SV Angel2 shared
Forbion1 shared
Eli Lilly and Company1 shared
Versant Ventures1 shared
Accel1 shared
Rethink Impact1 shared
Samsung Next1 shared
Khosla Ventures1 shared
GingerBread Capital1 shared
Primetime Partners1 shared
Andreessen Horowitz1 shared
Premji Invest1 shared
Memorial Hermann Health System1 shared
WellSpan Health1 shared
Lux Capital1 shared
Bessemer Venture Partners1 shared
Character1 shared
Last updated: 15 April 2026